SERENTIL® (MESORIDAZINE BESYLATE) HAS BEEN SHOWN TO PROLONG THE QTc INTERVAL IN A DOSE RELATED MANNER, AND DRUGS WITH THIS POTENTIAL, INCLUDING SERENTIL, HAVE BEEN ASSOCIATED WITH TORSADE DE POINTES-TYPE ARRHYTHMIAS AND SUDDEN DEATH. DUE TO ITS POTENTIAL FOR SIGNIFICANT, POSSIBLY LIFE-THREATENING, PROARRHYTHMIC EFFECTS, SERENTIL SHOULD BE RESERVED FOR USE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS WHO FAIL TO SHOW AN ACCEPTABLE RESPONSE TO ADEQUATE COURSES OF TREATMENT WITH OTHER ANTIPSYCHOTIC DRUGS, EITHER BECAUSE OF INSUFFICIENT EFFECTIVENESS OR THE INABILITY TO ACHIEVE AN EFFECTIVE DOSE DUE TO INTOLERABLE ADVERSE EFFECTS FROM THOSE DRUGS. (SEE WARNINGS, CONTRAINDICATIONS, AND INDICATIONS.)
SERENTIL® (mesoridazine besylate), the besylate salt of a metabolite of thioridazine, is a phenothiazine antipsychotic. Serentil is 10-[2(1-methyl-2-piperidyl)ethyl]-2-(methyl-sulfinyl)-phenothiazine [as the besylate].
Serentil® (mesoridazine besylate) is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life-threatening, proarrhythmic effects with Serentil treatment, Serentil should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with Serentil, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS).
However, the prescriber should be aware that Serentil has not been systematically evaluated in controlled trials in treatment of refractory schizophrenic patients and its efficacy in such patients is unknown.
Media Articles Related to Serentil (Mesoridazine)
EndoBreak: Blood Glucose and Schizophrenia; New Top Doc at ADA
Source: MedPageToday.com - medical news plus CME for physicians [2017.01.13]
(MedPage Today) -- News and commentary from the endocrinology world
Marijuana use and schizophrenia: New evidence suggests link
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2016.12.26]
Recent findings appear to reconfirm evidence of a two-way link between schizophrenia and cannabis use, suggesting that one leads to the other.
Sleep disruption has genetic links with obesity, schizophrenia
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2016.12.20]
Genome analysis of over 112,500 participants in the UK Biobank links self-reported sleep disruption to obesity, restless legs syndrome, and schizophrenia.
ADHD and Schizophrenia: Similarities and Differences
Source: ADHD / ADD News From Medical News Today [2016.12.06]
ADHD and schizophrenia are two different disorders, but there is an overlap in symptoms. Learn about their causes, symptoms, and treatments.
MicroRNA may give clue to schizophrenia's 'voices'
Source: Schizophrenia News From Medical News Today [2016.11.29]
Research using a mouse model of schizophrenia unearths clues about the origin of auditory hallucinations and the potential for innovative, new treatments.
Published Studies Related to Serentil (Mesoridazine)
Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. [2007.11]
We compared the effects of single doses of thioridazine and mesoridazine on the heart rate-corrected QT (QTc) interval in healthy adult volunteers. QTc intervals and plasma concentrations of thioridazine, mesoridazine, and metabolites were measured after single oral doses of thioridazine hydrochloride 50 mg, mesoridazine besylate 50 mg, or placebo in a double-blind, crossover study...
Clinical Trials Related to Serentil (Mesoridazine)
Reducing Antipsychotic-Induced Weight Gain in Children With Metformin [Recruiting]
Recent but limited short term studies have shown that Metformin can slow down weight gain in
obese children and in children with psychotropic-induced weight gain, two distinct pediatric
populations that are at risk for obesity related co-morbid conditions. The purpose of this
study is to conduct a long term prospective pilot cohort study to investigate the use of
Metformin to prevent or decrease weight gain in two cohorts of children: 1) children with
psychotropic induced weight gain on Metformin and 2) children with BMI above the 95th
percentile on Metformin. Both study populations will be enrolled in a lifestyle weight
Page last updated: 2017-01-13